GlassScriptPhysician profile
Gregory D Hazergian
NPI 1588923734
$15,286.10
in general payments reported to CMS, 2019-2025
36 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $1,539 · 2021: $2,531 · 2022: $2,285 · 2023: $3,352 · 2024: $3,396 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,035 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,035.48 |
| Education | $118.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,050.48 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,830.69 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $1,244.99 | 2022-2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,170.98 | 2019-2025 | Lifevest |
| Pfizer INC. | $939.29 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $808.38 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $797.72 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $675.79 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $597.29 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $594.59 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $582.45 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $506.37 | 2019-2024 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $492.06 | 2019-2020 | |
| Amgen INC. | $401.32 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $392.14 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $333.02 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $250.47 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $226.39 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Heartflow, INC. | $225.01 | 2022-2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $157.50 | 2019-2024 | |
| Biosense Webster, INC. | $145.83 | 2025 | Carto 3 |
| Boston Scientific Corporation | $145.75 | 2020-2023 | |
| Edwards Lifesciences Corporation | $112.94 | 2019-2022 | |
| Lilly USA, LLC | $100.16 | 2023-2024 | Mounjaro, Zepbound |
| United Therapeutics Corporation | $98.09 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.94 | 2021-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $53.87 | 2024 | Arcalyst |
| Astellas Pharma US INC | $45.08 | 2023 | Lexiscan |
| Impulse Dynamics (USA) INC. | $44.81 | 2022-2023 | Optimizer |
| Lundbeck LLC | $42.26 | 2019-2021 | |
| Philips North America LLC | $37.80 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $33.39 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $25.66 | 2023 | Injectafer |
| Medtronic, INC. | $19.93 | 2023 | Micra |
| Abbott Laboratories | $17.14 | 2023 | Cardiomems |
| Preventice Services, LLC | $15.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hazergian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.